Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 58

1.

Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials.

Oostvogels L, Heineman TC, Johnson RW, Levin MJ, McElhaney JE, Van den Steen P, Zahaf T, Dagnew AF, Chlibek R, Diez-Domingo J, Gorfinkel IS, Hervé C, Hwang SJ, Ikematsu H, Kalema G, Lal H, McNeil SA, Mrkvan T, Pauksens K, Smetana J, Watanabe D, Weckx LY, Cunningham AL.

Hum Vaccin Immunother. 2019 Jun 28:1-8. doi: 10.1080/21645515.2019.1627818. [Epub ahead of print]

PMID:
31216205
2.

Tissue Imaging by Mass Spectrometry: A Practical Guide for the Medicinal Chemist.

Johnson RW Jr, Talaty N.

ACS Med Chem Lett. 2019 Jan 11;10(2):161-167. doi: 10.1021/acsmedchemlett.8b00480. eCollection 2019 Feb 14.

PMID:
30783497
3.

Quality of Life impact of a Recombinant Zoster Vaccine in adults ≥50 Years of Age.

Curran D, Oostvogels L, Heineman T, Matthews S, McElhaney J, McNeil S, Diez-Domingo J, Lal H, Andrews C, Athan E, Berglund J, Campora L, de Looze F, Korhonen T, Leung E, Levin M, Volpi A, Johnson RW; ZOE-50/70 study group.

J Gerontol A Biol Sci Med Sci. 2018 Jun 27. doi: 10.1093/gerona/gly150. [Epub ahead of print]

PMID:
29955836
4.

Complications of herpes zoster in immunocompetent older adults: Incidence in vaccine and placebo groups in two large phase 3 trials.

Kovac M, Lal H, Cunningham AL, Levin MJ, Johnson RW, Campora L, Volpi A, Heineman TC; ZOE-50/70 Study Group.

Vaccine. 2018 Mar 14;36(12):1537-1541. doi: 10.1016/j.vaccine.2018.02.029. Epub 2018 Feb 17.

5.

Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective.

Johnson RW, Alvarez-Pasquin MJ, Bijl M, Franco E, Gaillat J, Clara JG, Labetoulle M, Michel JP, Naldi L, Sanmarti LS, Weinke T.

Ther Adv Vaccines. 2015 Jul;3(4):109-20. doi: 10.1177/2051013615599151. Review. Erratum in: Ther Adv Vaccines. 2016 Jan;4(1-2):32.

6.
7.

Clinical practice. Postherpetic neuralgia.

Johnson RW, Rice AS.

N Engl J Med. 2014 Oct 16;371(16):1526-33. doi: 10.1056/NEJMcp1403062. Review. No abstract available.

PMID:
25317872
8.

Effects of calibration approaches on the accuracy for LC-MS targeted quantification of therapeutic protein.

Nouri-Nigjeh E, Zhang M, Ji T, Yu H, An B, Duan X, Balthasar J, Johnson RW, Qu J.

Anal Chem. 2014 Apr 1;86(7):3575-84. doi: 10.1021/ac5001477. Epub 2014 Mar 21.

9.

Similar herpes zoster incidence across Europe: results from a systematic literature review.

Pinchinat S, Cebrián-Cuenca AM, Bricout H, Johnson RW.

BMC Infect Dis. 2013 Apr 10;13:170. doi: 10.1186/1471-2334-13-170. Review.

10.

Vaccination against herpes zoster in developed countries: state of the evidence.

Drolet M, Oxman MN, Levin MJ, Schmader KE, Johnson RW, Patrick D, Mansi JA, Brisson M.

Hum Vaccin Immunother. 2013 May;9(5):1177-84. doi: 10.4161/hv.23491. Epub 2013 Jan 16. Review.

11.

Analysis of chloroquine and metabolites directly from whole-body animal tissue sections by liquid extraction surface analysis (LESA) and tandem mass spectrometry.

Parson WB, Koeniger SL, Johnson RW, Erickson J, Tian Y, Stedman C, Schwartz A, Tarcsa E, Cole R, Van Berkel GJ.

J Mass Spectrom. 2012 Nov;47(11):1420-8. doi: 10.1002/jms.3068.

PMID:
23147817
12.

Implementation of proteomic biomarkers: making it work.

Mischak H, Ioannidis JP, Argiles A, Attwood TK, Bongcam-Rudloff E, Broenstrup M, Charonis A, Chrousos GP, Delles C, Dominiczak A, Dylag T, Ehrich J, Egido J, Findeisen P, Jankowski J, Johnson RW, Julien BA, Lankisch T, Leung HY, Maahs D, Magni F, Manns MP, Manolis E, Mayer G, Navis G, Novak J, Ortiz A, Persson F, Peter K, Riese HH, Rossing P, Sattar N, Spasovski G, Thongboonkerd V, Vanholder R, Schanstra JP, Vlahou A.

Eur J Clin Invest. 2012 Sep;42(9):1027-36. doi: 10.1111/j.1365-2362.2012.02674.x. Epub 2012 Apr 21.

13.

Prevention of herpes zoster pain.

Johnson RW, Higa K.

Pain Manag. 2012 Jan;2(1):63-9. doi: 10.2217/pmt.11.81.

PMID:
24654619
14.

Characterization of cis-regulatory elements controlling repo transcription in Drosophila melanogaster.

Johnson RW, Wood JL, Jones BW.

Gene. 2012 Jan 15;492(1):167-76. doi: 10.1016/j.gene.2011.10.032. Epub 2011 Oct 25.

PMID:
22051777
15.

A quantitation method for mass spectrometry imaging.

Koeniger SL, Talaty N, Luo Y, Ready D, Voorbach M, Seifert T, Cepa S, Fagerland JA, Bouska J, Buck W, Johnson RW, Spanton S.

Rapid Commun Mass Spectrom. 2011 Feb 28;25(4):503-10. doi: 10.1002/rcm.4891.

PMID:
21259359
16.

A prospective study of the herpes zoster severity of illness.

Drolet M, Brisson M, Levin MJ, Schmader KE, Oxman MN, Johnson RW, Camden S, Mansi JA.

Clin J Pain. 2010 Oct;26(8):656-66. doi: 10.1097/AJP.0b013e3181eef686.

PMID:
20842005
17.

The impact of herpes zoster and post-herpetic neuralgia on quality-of-life.

Johnson RW, Bouhassira D, Kassianos G, Leplège A, Schmader KE, Weinke T.

BMC Med. 2010 Jun 21;8:37. doi: 10.1186/1741-7015-8-37.

18.

The impact of varicella zoster virus: chronic pain.

Opstelten W, McElhaney J, Weinberger B, Oaklander AL, Johnson RW.

J Clin Virol. 2010 May;48 Suppl 1:S8-13. doi: 10.1016/S1386-6532(10)70003-2. Review.

PMID:
20510265
19.

A GVF Zoster Workshop.

Johnson RW.

J Clin Virol. 2010 May;48 Suppl 1:S1. doi: 10.1016/S1386-6532(10)00188-5. No abstract available.

PMID:
20510261
20.

Herpes zoster and postherpetic neuralgia.

Johnson RW.

Expert Rev Vaccines. 2010 Mar;9(3 Suppl):21-6. doi: 10.1586/erv.10.30. Review.

PMID:
20192714

Supplemental Content

Loading ...
Support Center